Fig. 7.

Fig. 7.

ANKRD26 is a potential modifier of the thrombotic thrombocytopenic purpura phenotype. (A-C) Total (A), young (B) and mature (C) thrombocyte counts in zebrafish (6-8 months old) of different genotypes as indicated. Data are presented as individual values, mean (bars) and s.e.m. (horizontal lines). Kruskal–Wallis analysis was performed to determine statistical significance. (D,E) Flow cytometric analysis showing the percentage of ANKRD26-positive (Q1+Q2) cells in the peripheral blood buffy coat from unaffected controls (Ctrl.; D) and patients with immune thrombotic thrombocytopenic purpura (iTTP; E). (F) Quantification of ANKRD26-positive cells in the controls (n=4) and patients with iTTP (n=4). (G) Confocal fluorescent imaging showing the expression of ANKRD26 (green) and glycoprotein 1bα protein (CD41a; red) in megakaryocytes from peripheral blood smears of patients with iTTP. The nucleus was stained with DAPI (blue). (H) Western blot analysis demonstrating the levels of ANKRD26 protein in platelet lysates of controls and patients with iTTP. (I) Quantitation of plasma levels of soluble ANKRD26 protein in unaffected controls (n=11) and patients with iTTP (n=25). *P<0.05, **P<0.01, ***P<0.005, and ****P<0.0001.